Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2988MR)

This product GTTS-WQ2988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2988MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13826MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ11199MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ6879MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ15844MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ11897MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ8369MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ8711MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW